CellCarta
Mark Kockx is a seasoned medical and scientific leader with extensive experience in pathology and fundamental clinical research. As Chief Medical & Scientific Officer and a board member at CellCarta since April 2001, Mark Kockx also co-founded HistoGeneX, which is now part of CellCarta. Previous roles include serving as Head of the Department of Pathology at ZNA from 1994 to 2011 and managing fundamental clinical research at the Fonds Wetenschappelijk Onderzoek - Vlaanderen. Mark Kockx's academic background includes a combined MD and PhD in Medicine from the University of Antwerp, completed in 1994.
This person is not in any offices
CellCarta
CellCarta's Mission is centered on collaborating and partnering with pharmaceutical and biotech companies through proteomics and immune monitoring enabling the acceleration of precision medicine in drug development.With a vision and deep understanding of the needs for complex immune monitoring in novel drug development, Caprion integratedImmuneCarta (formerly known as National Immune Monitoring), with its established and proven proteomics service, ProteoCarta. Together, Caprion now offers a fully integrated and unique service offering to its partners.